



## Model List of Essential Medicines



### Amikacin [General information](#)

#### Section

#### Access group antibiotics

- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)
- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
- Parenteral > General injections > unspecified: 50 mg per mL in 2 mL vial (as sulfate); 250 mg per mL in 2 mL vial (as sulfate)

#### Indications

#### First choice

[Neutropenia \(high-risk\)](#) co-prescribed with [cefotaxime Inflammatory and other diseases of prostate \(severe\)](#) co-prescribed with [cefotaxime Acute pyelonephritis \(severe\)](#) co-prescribed with [ceftriaxone Inflammatory and other diseases of prostate \(severe\)](#) co-prescribed with [ceftriaxone Acute pyelonephritis \(severe\)](#)

#### Second choice

co-prescribed with [cloxacillin Sepsis without septic shock](#)

#### Section

#### Antituberculosis medicines

- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

#### Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



### Amoxicillin [General information](#)

#### Section

#### Access group antibiotics

- Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
- Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
- Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)
- Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)
- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)

#### Indications

#### First choice

[Acute pharyngitis](#) [Periapical abscess without sinus](#) [Acute sinusitis](#) [Acute otitis media](#) [Chronic obstructive](#)

[pulmonary disease with acute exacerbation](#) [Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Acute malnutrition in infants, children or adolescents \(uncomplicated\) \[children\]](#) [Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) co-prescribed with [gentamicin](#) [Sepsis without septic shock](#)

**Second choice**

[Bacterial meningitis](#)

Other indications

[Bacterial infection of unspecified site](#) [Infectious cystitis](#)

**Amoxicillin + clavulanic acid** [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
- Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

**First choice**

[Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Infectious cystitis](#) [Neutropenia \(low-risk\)](#) [Other specified pneumonia \(Hospital-acquired pneumonia\)](#) [Bacterial cellulitis, erysipelas or lymphangitis](#) [Peritonitis \(mild-moderate\)](#) [Acute sinusitis](#) [Peritoneal abscess \(mild-moderate\)](#) [Chronic obstructive pulmonary disease with acute exacerbation](#)

**Second choice**

[Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) [Bacterial infection of joint](#) [Other specified prophylactic measures](#) [Osteomyelitis or osteitis](#) [Acute otitis media](#)

Other indications

[Bacterial infection of unspecified site](#)

Section

Antituberculosis medicines

- Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

**Ampicillin** [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
- Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

**First choice**

[Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) [Peritonitis \(mild-moderate\)](#) [Peritonitis \(severe\)](#) [Peritoneal abscess \(mild-moderate\)](#) [Peritoneal abscess \(severe\)](#) co-prescribed with [gentamicin](#) [Sepsis without septic shock](#)

**Second choice**

[Bacterial meningitis](#)

Other indications

[Bacterial infection of unspecified site](#)

### **Azithromycin** [General information](#)

Section

Watch group antibiotics

- Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

**First choice**

[Trachoma](#) [Cholera](#) [Cholera \[children\]](#) [Paratyphoid fever](#) [Chlamydia trachomatis](#) [Typhoid fever](#) [Yaws](#) co-prescribed with [ceftriaxone](#) [Gonococcal infection](#)

**Second choice**

[Infectious gastroenteritis or colitis without specification of infectious agent](#) co-prescribed with [cefixime](#) [Gonococcal infection](#)

### **Aztreonam** [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection

Indications

[Other specified bacterial diseases](#)

### **Bedaquiline** [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > tablet: 100 mg tablet; 20 mg tablet

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

### **Benzathine benzylpenicillin** [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > IM: 1.2 million IU in vial ( $\approx$  900 mg) powder for injection; 2.4 million IU in vial ( $\approx$  1.8 g) powder for injection

Indications

**First choice**

[Congenital syphilis \[children\]](#) [Syphilis](#)

Other indications

[Bacterial infection of unspecified site](#)

### **Benzylpenicillin** [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
- Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)

Indications

**First choice**

[Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Congenital syphilis \[children\]](#) [Syphilis](#) [Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) co-prescribed with [gentamicin](#) [Sepsis without septic shock](#)

**Second choice**

[Bacterial meningitis](#)

Other indications

[Bacterial infection of unspecified site](#)

**Capreomycin [General information](#)**

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1000 mg powder for injection (vial)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

**Cefalexin [General information](#)**

Section

Access group antibiotics

- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid: 250 mg (as monohydrate)
- Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)
- Oral > Solid > dispersible tablet: 125 mg; 250 mg

Indications

**First choice**

[Bacterial cellulitis, erysipelas or lymphangitis](#)

**Second choice**

[Chronic obstructive pulmonary disease with acute exacerbation Acute pharyngitis](#)

Other indications

[Bacterial infection of unspecified site](#)

**Cefazolin [General information](#)**

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection

Indications

**First choice**

[Other specified prophylactic measures Other specified prophylactic measures](#)

**Second choice**

[Bacterial infection of joint Osteomyelitis or osteitis](#)

Other indications

[Surgical site infection](#)

**Cefepime [General information](#)**

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection

Indications

[Other specified bacterial diseases](#)

**Cefiderocol [General information](#)**

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales](#)

**Cefixime [General information](#)**

Section

Watch group antibiotics

- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)

Indications

Second choice

[Infectious gastroenteritis or colitis without specification of infectious agent](#) [Gonococcal infection](#)

**Cefotaxime** [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

First choice

[Bacterial meningitis](#) [Inflammatory and other diseases of prostate \(severe\)](#) [Acute pyelonephritis \(severe\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) [Peritoneal abscess \(mild-moderate\)](#) [Peritoneal abscess \(severe\)](#) [Other specified pneumonia \(Hospital-acquired pneumonia\)](#) [Peritonitis \(mild-moderate\)](#) [Peritonitis \(severe\)](#)

Second choice

[Inflammatory and other diseases of prostate \(mild to moderate\)](#) [Acute pyelonephritis \(mild to moderate\)](#) [Sepsis without septic shock](#) [Bacterial infection of joint](#) [Osteomyelitis or osteitis](#)

Other indications

[Bacterial infection of unspecified site](#)

**Ceftaroline** [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection

Indications

[Other specified bacterial diseases](#)

**Ceftazidime** [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection

Indications

First choice

[Endophthalmitis](#)

Other indications

[Pseudomonas aeruginosa resistant to other antibiotic](#)

**Ceftazidime + avibactam** [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Enterobacterales](#)

**Ceftolozane + tazobactam** [General information](#)

## Section

### Reserve group antibiotics

- Parenteral > General injections > IV: 1 g + 0.5 g powder for injection

### Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#)



## Ceftriaxone [General information](#)

## Section

### Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

### Indications

#### First choice

[Inflammatory and other diseases of prostate \(severe\)](#) [Bacterial meningitis](#) [Acute pyelonephritis \(severe\)](#) [Other specified pneumonia \(Hospital-acquired pneumonia\)](#) [Paratyphoid fever](#) [Typhoid fever](#) [Peritonitis \(mild-moderate\)](#) [Peritonitis \(severe\)](#) [Peritoneal abscess \(mild-moderate\)](#) [Peritoneal abscess \(severe\)](#) [Gonococcal infection](#) [Endophthalmitis](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) [children] co-prescribed with [metronidazole](#) [Necrotising fasciitis](#)

#### Second choice

[Inflammatory and other diseases of prostate \(mild to moderate\)](#) [Acute pyelonephritis \(mild to moderate\)](#) [Infectious gastroenteritis or colitis without specification of infectious agent](#) [Bacterial infection of joint](#) [Sepsis without septic shock](#) [Osteomyelitis or osteitis](#)

#### Other indications

[Bacterial infection of unspecified site](#)



## Cefuroxime [General information](#)

## Section

### Watch group antibiotics

- Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection

### Indications

#### Second choice

[Other specified prophylactic measures](#)



## Chloramphenicol [General information](#)

## Section

### Access group antibiotics

- Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
- Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
- Oral > Liquid: 150 mg per 5 mL (as palmitate)
- Oral > Solid: 250 mg capsule

### Indications

#### Second choice

[Bacterial meningitis](#)

#### Other indications

[Bacterial infection of unspecified site](#)



## **Ciprofloxacin [General information](#)**

### Section

#### Watch group antibiotics

- Parenteral > General injections > IV: 2 mg per mL (as hyclate)
- Oral > Liquid: 250 mg per 5 mL (anhydrous)
- Oral > Solid: 250 mg (as hydrochloride)
- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)
- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)

#### Indications

##### First choice

[Acute pyelonephritis \(mild to moderate\)](#) [Infectious gastroenteritis or colitis without specification of infectious agent](#) [Paratyphoid fever](#) [Typhoid fever](#) [Neutropenia \(low-risk\)](#) [Inflammatory and other diseases of prostate \(mild to moderate\)](#)

##### Second choice

[Cholera](#) [Cholera \[children\]](#) [Peritonitis \(mild-moderate\)](#) [Peritoneal abscess \(mild-moderate\)](#)

#### Other indications

[Bacterial infection of unspecified site](#)

## **Clarithromycin [General information](#)**

### Section

#### Watch group antibiotics

- Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid
- Parenteral > General injections > unspecified: 500 mg in vial powder for injection
- Oral > Solid > dosage form: 500 mg; 250 mg
- Oral > Solid > dosage form: 500 mg

#### Indications

##### First choice

co-prescribed with [cefotaxime](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) co-prescribed with [ceftriaxone](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#)

##### Second choice

[Acute pharyngitis](#) co-prescribed with [amoxicillin + clavulanic acid](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#)

#### Other indications

[Helicobacter pylori associated gastric ulcer](#)

## **Clindamycin [General information](#)**

### Section

#### Access group antibiotics

- Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride) capsule
- Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection
- Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)
- Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride)

#### Indications

##### First choice

[Necrotising fasciitis](#)

##### Second choice

[Bacterial infection of joint](#) [Osteomyelitis or osteitis](#)

#### Other indications

[Bacterial infection of unspecified site](#)

## **Clofazimine [General information](#)**

## Section

### Antituberculosis medicines

- Oral > Solid > dosage form: 100 mg; 50 mg

### Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

## Section

### Antileprosy medicines

- Oral > Solid > dosage form: 100 mg; 50 mg

### Indications

[Leprosy](#)



## **Cloxacillin** [General information](#)

## Section

### Access group antibiotics

- Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid
- Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule
- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection
- Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid
- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection
- Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)

### Indications

#### First choice

[Osteomyelitis or osteitis](#) [Bacterial infection of joint](#) [Bacterial cellulitis, erysipelas or lymphangitis](#)

#### Second choice

co-prescribed with [amikacin Sepsis without septic shock](#)

### Other indications

[Bacterial infection of unspecified site](#)



## **Colistin (injection)** [General information](#)

## Section

### Reserve group antibiotics

- Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium)
- Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium) (equivalent to 34 mg colistin base activity)

### Indications

[Other specified bacterial diseases](#) [Carbapenem resistant Acinetobacter baumannii](#) [Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Enterobacterales](#)



## **Cycloserine** [General information](#)

## Section

### Antituberculosis medicines

- Oral > Solid > dosage form: 250 mg; 125 mg

### Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



## **Dapsone** [General information](#)

## Section

### Antileprosy medicines

- Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet

### Indications

[Leprosy](#)



## **Daptomycin** [General information](#)

## Section

### Reserve group antibiotics

- Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection

Indications

[Other specified bacterial diseases](#)

**Delafloxacin [General information](#)**

Section

Watch group antibiotics

- Parenteral > General injections > IV: 300 mg lyophilized powder for injection
- Oral > Solid: 450 mg

Indications

[Methicillin resistant Staphylococcus aureus](#)

**Delamanid [General information](#)**

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 25 mg
- Oral > Solid > tablet: 50 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

**Doxycycline [General information](#)**

Section

Access group antibiotics

- Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)
- Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)
- Parenteral > General injections > unspecified: 100 mg in vial powder for injection
- Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)
- Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
- Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)
- Oral > Solid > dosage form: 100 mg (as hyclate)

Indications

**First choice**

[Cholera Chlamydia trachomatis](#)

**Second choice**

[Cholera \[children\] Chronic obstructive pulmonary disease with acute exacerbation Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\)](#)

Other indications

[Bacterial infection of unspecified site](#)

**Eravacycline [General information](#)**

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 50 mg lyophilized powder for injection

Indications

[Carbapenem resistant Enterobacterales](#)

**Erythromycin [General information](#)**

Section

Watch group antibiotics

- Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)
- Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)
- Oral > Solid: 250 mg (as stearate or ethylsuccinate)

Indications

**Second choice**

Therapeutic equivalent to [clarithromycin](#) for [Acute pharyngitis](#)

Other indications

[Bacterial infection of unspecified site](#)

**Ethambutol [General information](#)**

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL
- Oral > Solid > dispersible tablet: 100 mg
- Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)

Indications

[Other specified tuberculosis Tuberculosis](#)

**Ethambutol + isoniazid [General information](#)**

Section

Antituberculosis medicines

- Oral > Solid: 400 mg + 150 mg tablet

Indications

[Tuberculosis](#)

**Ethambutol + isoniazid + pyrazinamide + rifampicin [General information](#)**

Section

Antituberculosis medicines

- Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet

Indications

[Tuberculosis](#)

**Ethambutol + isoniazid + rifampicin [General information](#)**

Section

Antituberculosis medicines

- Oral > Solid: 275 mg + 75 mg + 150 mg tablet

Indications

[Tuberculosis](#)

**Ethionamide [General information](#)**

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 125 mg
- Oral > Solid > tablet: 250 mg

Indications

[Tuberculous meningitis Multi-drug resistant Mycobacterium tuberculosis](#)

**Fifth generation cephalosporins [General information](#)**

Section

Reserve group antibiotics

- .

Indications

[Other specified bacterial diseases](#)

**Flomoxef [General information](#)**

Section

Watch group antibiotics

- Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection

Indications

[Other specified other antibiotic resistant Enterobacterales](#)

**Fosfomycin (injection) [General information](#)**

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection

Indications

[Other specified bacterial diseases](#) [Carbapenem resistant Acinetobacter baumannii](#) [Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Enterobacterales](#)



#### **Fourth generation cephalosporins** [General information](#)

Section

Watch group antibiotics

- .

Indications

[Other specified bacterial diseases](#)



#### **Gatifloxacin** [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 200 mg; 400 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



#### **Gentamicin** [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)

Indications

**First choice**

[Neonatal meningitis](#) [Sepsis without septic shock](#) [Sepsis without septic shock](#) [Sepsis without septic shock](#) co-prescribed with [amoxicillin Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) co-prescribed with [ampicillin Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) co-prescribed with [ampicillin Peritonitis \(mild-moderate\)](#) co-prescribed with [ampicillin Peritonitis \(severe\)](#) co-prescribed with [ampicillin Peritoneal abscess \(mild-moderate\)](#) co-prescribed with [ampicillin Peritoneal abscess \(severe\)](#) co-prescribed with [ampicillin Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) co-prescribed with [benzylpenicillin Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) co-prescribed with [benzylpenicillin Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#)

**Second choice**

[Gonococcal infection](#) [Other specified prophylactic measures](#)

Other indications

[Bacterial infection of unspecified site](#)



#### **Imipenem + cilastatin** [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection

Indications

**Second choice**

Therapeutic equivalent to [meropenem](#) for [Peritonitis \(severe\)](#) Therapeutic equivalent to [meropenem](#) for [Peritoneal abscess \(severe\)](#) Therapeutic equivalent to [meropenem](#) for [Neutropenia \(high-risk\)](#)

Other indications

[Pseudomonas aeruginosa resistant to other antibiotic](#) [Antibiotic resistant Acinetobacter baumannii](#)

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to [meropenem](#) for [Multi-drug resistant Mycobacterium tuberculosis](#)



#### **Imipenem + cilastatin + relebactam** [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection
- Parenteral > General injections > IV: 500 mg (as monohydrate) + 500 mg (as sodium) + 250 mg (as monohydrate) powder for injection

Indications

[Carbapenem resistant Enterobacterales](#) [Other specified other antibiotic resistant Enterobacterales](#) [Carbapenem-resistant Pseudomonas aeruginosa](#)



**Isoniazid** [General information](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 100 mg per mL
- Oral > Solid > dispersible tablet: 100 mg (scored)
- Oral > Solid > tablet: 100 mg; 300 mg

Indications

[Other specified tuberculosis](#) [Tuberculosis](#)



**Isoniazid + pyrazinamide + rifampicin** [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg

Indications

[Tuberculosis](#)



**Isoniazid + rifampicin** [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 50 mg + 75 mg
- Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg

Indications

[Tuberculosis](#)



**Isoniazid + rifapentine** [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 300 mg + 300 mg tablet (scored)

Indications

[Latent tuberculosis](#)



**Kanamycin (injection)** [General information](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1000 mg powder for injection (vial)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



**Levofloxacin** [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 100 mg
- Oral > Solid > tablet: 250 mg; 500 mg; 750 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



**Linezolid** [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 mg per mL in 300 mL bag

- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid: 400 mg tablet; 600 mg tablet
- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 600 mg

Indications

[Other specified bacterial diseases Methicillin resistant Staphylococcus aureus Vancomycin resistant Staphylococcus aureus Vancomycin resistant Enterococcus](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 150 mg (scored)
- Oral > Solid > tablet: 600 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



#### **Meropenem [General information](#)**

Section

Watch group antibiotics

- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Indications

**Second choice**

[Neonatal meningitis Peritonitis \(severe\) Peritoneal abscess \(severe\) Neutropenia \(high-risk\)](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



#### **Meropenem + vaborbactam [General information](#)**

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales Carbapenem resistant Acinetobacter baumannii](#)



#### **Metronidazole [General information](#)**

Section

Access group antibiotics

- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Oral > Solid: 200 to 500 mg tablet
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
- Local > Rectal > Suppository: 500 mg; 1 g
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial
- Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
- Oral > Solid > tablet: 500 mg; 200 mg; 250 mg; 400 mg

Indications

**First choice**

[Intestinal infections due to Clostridioides difficile Trichomoniasis Necrotising fasciitis](#) co-prescribed with [cefazolin](#)  
[Other specified prophylactic measures](#) co-prescribed with [cefotaxime Peritoneal abscess \(mild-moderate\)](#) co-prescribed with [cefotaxime Peritoneal abscess \(severe\)](#) co-prescribed with [cefotaxime Peritonitis \(mild-moderate\)](#)  
 co-prescribed with [cefotaxime Peritonitis \(severe\)](#) co-prescribed with [ceftriaxone Peritoneal abscess \(mild-moderate\)](#) co-prescribed with [ceftriaxone Peritoneal abscess \(severe\)](#) co-prescribed with [ceftriaxone Peritonitis \(mild-moderate\)](#) co-prescribed with [ceftriaxone Peritonitis \(severe\)](#)

**Second choice**

co-prescribed with [ciprofloxacin Peritoneal abscess \(mild-moderate\)](#) co-prescribed with [ciprofloxacin Peritonitis \(mild-moderate\)](#)

Other indications

[Bacterial infection of unspecified site](#)



**Moxifloxacin [General information](#)**

Section

Antituberculosis medicines

- Oral > Solid > tablet: 400 mg
- Oral > Solid > dispersible tablet: 100 mg

Indications

[Tuberculosis Multi-drug resistant Mycobacterium tuberculosis](#)

**Nitrofurantoin [General information](#)**

Section

Access group antibiotics

- Oral > Liquid: 25 mg per 5 mL oral liquid
- Oral > Solid > dosage form: 100 mg; 50 mg

Indications

**First choice**

[Infectious cystitis](#)

**Ofloxacin [General information](#)**

Section

Antituberculosis medicines

- Oral > Solid: 200 mg; 400 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

**Omadacycline [General information](#)**

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 100 mg lyophilized powder for injection
- Oral > Solid: 300 mg

Indications

[Methicillin resistant Staphylococcus aureus](#)

**Oxazolindinones [General information](#)**

Section

Reserve group antibiotics

- .

Indications

[Other specified bacterial diseases](#)

**P-aminosalicylate sodium [General information](#)**

Section

Antituberculosis medicines

- Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

**P-aminosalicylic acid [General information](#)**

Section

Antituberculosis medicines

- Oral > Solid: 4 g granules in sachet

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

**Phenoxyethylpenicillin [General information](#)**

Section

Access group antibiotics

- Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
- Oral > Solid: 250 mg (as potassium salt) tablet
- Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)

Indications

**First choice**

[Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\)](#) [Periapical abscess without sinus](#) [Acute pharyngitis](#)

Other indications

[Bacterial infection of unspecified site](#)

**Piperacillin + tazobactam** [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection

Indications

**First choice**

[Neutropenia \(high-risk\)](#) [Other specified pneumonia \(Hospital-acquired pneumonia\)](#) [Peritonitis \(severe\)](#) [Peritoneal abscess \(severe\)](#) co-prescribed with [clindamycin](#) [Necrotising fasciitis](#)

**Plazomicin** [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500 mg per 10 mL

Indications

[Carbapenem resistant Acinetobacter baumannii](#) [Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Enterobacterales](#)

**Polymyxin B (injection)** [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)

Indications

[Carbapenem resistant Acinetobacter baumannii](#) [Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Enterobacterales](#)

**Polymyxins** [General information](#)

Section

Reserve group antibiotics

- .

Indications

[Other specified bacterial diseases](#)

**Pretomanid** [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > tablet: 200 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

**Procaine benzylpenicillin** [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million

IU) powder for injection

Indications

**First choice**

[Congenital syphilis \[children\]](#)

**Second choice**

[Syphilis](#)

**Protionamide [General information](#)**

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to [ethionamide](#) for [Multi-drug resistant Mycobacterium tuberculosis](#)

**Pyrazinamide [General information](#)**

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 400 mg; 500 mg

Indications

[Tuberculosis](#)

**Rifabutin [General information](#)**

Section

Antituberculosis medicines

- Oral > Solid: 150 mg

Indications

[Tuberculosis](#)

**Rifampicin [General information](#)**

Section

Antituberculosis medicines

- Oral > Liquid: 20 mg per mL
- Oral > Solid: 150 mg; 300 mg
- Parenteral > General injections > IV: 600 mg in vial powder for injection

Indications

[Tuberculosis Other specified tuberculosis](#)

Section

Antileprosy medicines

- Oral > Liquid: 20 mg per mL
- Oral > Solid: 150 mg; 300 mg

Indications

[Leprosy](#)

**Rifapentine [General information](#)**

Section

Antituberculosis medicines

- Oral > Solid > tablet: 150 mg; 300 mg
- Oral > Solid > dispersible tablet: 150 mg

Indications

[Tuberculosis Latent tuberculosis](#)

**Spectinomycin [General information](#)**

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection

Indications

**Second choice**

[Gonococcal infection](#)

Other indications

[Bacterial infection of unspecified site](#)

**Streptomycin (injection) [General information](#)**

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

**Sulfamethoxazole + trimethoprim [General information](#)**

Section

Access group antibiotics

- Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule
- Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
- Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
- Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule
- Oral > Solid > dispersible tablet: 100 mg + 20 mg

Indications

**First choice**

[Infectious cystitis](#)

**Second choice**

[Infectious gastroenteritis or colitis without specification of infectious agent](#)

Other indications

[Bacterial infection of unspecified site](#)

**Tedizolid [General information](#)**

Section

Reserve group antibiotics

Indications

Therapeutic equivalent to [linezolid](#) for [Methicillin resistant Staphylococcus aureus](#) Therapeutic equivalent to [linezolid](#) for [Vancomycin resistant Staphylococcus aureus](#) Therapeutic equivalent to [linezolid](#) for [Vancomycin resistant Enterococcus](#)

**Terizidone [General information](#)**

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to [cycloserine](#) for [Multi-drug resistant Mycobacterium tuberculosis](#)

**Tetracycline [General information](#)**

Section

Access group antibiotics

- Oral > Solid: 250 mg (hydrochloride)

Indications

[Bacterial infection of unspecified site](#)

**Tigecycline [General information](#)**

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 50 mg in vial powder for injection

Indications

[Other specified bacterial diseases](#)



**Trimethoprim** [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 50 mg per mL
- Oral > Solid: 100 mg; 200 mg

Indications

**First choice**

[Infectious cystitis](#)



**Vancomycin** [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection
- Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)
- Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection
- Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection

Indications

**First choice**

[Necrotising fasciitis](#) co-prescribed with [ceftazidime](#) [Endophthalmitis](#) co-prescribed with [ceftriaxone](#) [Endophthalmitis](#)

**Second choice**

[Intestinal infections due to Clostridioides difficile](#) [Neutropenia \(high-risk\)](#)

Other indications

[Methicillin resistant Staphylococcus aureus](#)